An Open-Label, Multi-Center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients With Non-Small Cell Lung Cancer.
Latest Information Update: 22 Feb 2021
At a glance
- Drugs Patupilone (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 26 Aug 2015 Primary endpoint has been met. (Early progression (EP)) according to the results published in the Cancer
- 26 Aug 2015 Primary endpoint has been met. (Progression-free survival (PFS9w)) according to the results published in the Cancer
- 26 Aug 2015 Results published in the Cancer.